Business and Finance

The CRDMO’s acquisition of the Baltimore plant is expected to boost its biologics presence.

The partnership focuses on enhancing the patient experience by providing greater affordability and access to specialty meds.

The updated tax on Canadian imports will rise from 25% to 50%, taking effect March 12.

This link in the pharma supply chain is undergoing a major transformation propelled by technological advancements, regulatory changes, and evolving market dynamics, requiring industry leaders to adopt innovative strategies in order to remain competitive.

The US president delays tariffs that comply with the 2020 USMCA for one month, with reciprocal tariffs still expected to go into effect by April 2.

The agreement—powered by YASKAWA's Maholo robot—aims to address challenges in production and commercialization while offering access to academic and startup communities.

NovoCare will offer the GLP-1 injection to cash-paying patients for a discounted $499 per month.

The 25% tax on various imports have gone into effect, resulting in retaliatory tariffs from the impacted nations.

After an initial 30-day pause, the US president plans to re-enact the import taxes on the nation’s trading partners—while also doubling the 10% tariff on China.

The presidential action follows up on a 2019 final rule aimed at empowering patients and boosting competition among hospitals, group health plans, and health insurance issuers in both individual and group markets.

The injection for the treatment of psoriatic arthritis—among other indications—is a biosimilar to Stelara.

James D. Chambers, PhD, MPharm, MSc, professor of medicine at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, dives into why biosimilars contribute to a reduction in cost and increase in patient access, while highlighting challenges to adoption.

The timing for the potential tax is yet to be determined, as the industry awaits to see the impact it could bring.

A qualitative study examines how Medicaid telehealth reimbursement policies affect staffing and patient-centered care.

The company’s Mourenx plant in Southwest France aims to become an API network hub, with first supplies expected by next year.

These taxes on goods—with the potential to take effect in weeks or months—will vary by country, but rates could depend on regulations, industry subsidies, and other factors.

The facilities are expected to offer pharma shipment support by addressing time and temperature-specific requirements.

Trump raises the import tax to 25% on the former—while restoring the latter to 25%—in a move that could potentially take effect on March 4.

The agreement is centered around improving cell culture efficiency and CGT quality.

A cohort study investigates the magnitude of lost coverage among pediatric patients, following the conclusion of the pandemic public health emergency.

What factors should be considered—and how can both parties benefit long-term?

A survey study of US employers aims to determine whether they prioritize financial or nonfinancial criteria when selecting health plans.

The company cites a decline in sales and excess inventory as the main contributing factors.

However, the 10% tariff on imports from China went into effect this morning, with the nation imposing several of it own.

What implications will these have on the pharma supply chain?

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld value & access advisor for Schoonveld Advisory and author of The Price of Global Health, previews his upcoming February column.

A study explores dual-enrollment in these plans—compared to other Medicare Advantage plans— impacts North Carolina’s Medicaid fee-for-service spending.

The investment not only moves along the company’s efforts in advancing clinical studies, but also opens up 700 new jobs for the Greater Toronto area.

In the second part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Amanda Salindong, associate director of channel & distribution at Alnylam Pharmaceuticals, describes how she supports her organization’s channel strategy.

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Donald Prentiss, founder and CEO, Qualthera, explains how collaboration between compounding pharmacies, drug manufacturers, and telehealth platforms can drive success, despite the various litigations pertaining to GLP-1s that are currently taking place.